Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of MK-1167 added to acetylcholinesterase inhibitor therapy in mild to moderate Alzheimer's disease dementia
NL-OMON60547Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing MK-1167 + acetylcholinesterase inhibitor with Placebo + acetylcholinesterase inhibitor (2 arms). Primary endpoints: Change from baseline in ADAS-Cog11 total score at Week 24, Participants with one or more adverse events and 1 more. Started Apr 2025; status: completed.
02
Drugs
MK-1167
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NL-OMON60547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60547.